S&N settles whistleblower suit; LabCorp starts genomic diagnostics biz;

@FierceMedDev: Researchers develop self-powered pacemaker system based on automatic wristwatch. Article | Follow @FierceMedDev

@VarunSaxena2: Per Capita Medicare Spending Is Actually Falling. More from the NYT | Follow @VarunSaxena2

@MichaelGFierce: Artificial virus promises effective drug delivery and gene therapy. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce: Fingerprint scanning system could help track children's vaccinations in developing countries. More from MIT Technology Review | Follow @EmilyWFierce

> Smith & Nephew ($SNN) agreed to an $8.3 million settlement after a whistleblower exposed the company's attempts to pass off Malaysian-made products as manufactured in the U.S. Story

> LabCorp ($LH) launched a new business, Enlighten Health Genomic, to explore the diagnostic potential of next generation sequencing (NGS) technology. Release

> In a newly announced partnership, Covidien ($COV) is allowing Concord, NH-based health care company Geneia to sell its ZephyrLIFE remote patient monitoring services to patients with chronic illnesses. Story

Biotech News

@FierceBiotech: ICYMI: $GSK's new Boston collaboration chief goes 'anti-pharma' as he prowls for partners. Article | Follow @FierceBiotech

@JohnCFierce: In diabetes, everybody is trying to beat everybody on next steps. Which is why Afrezza continues to stand out as a lonely effort. | Follow @JohnCFierce

@DamianFierce: $KMDA won't let a little thing like missing its endpoints in PhII/III derail a regulatory filing. More | Follow @DamianFierce

@EmilyMFierce: FDA rushes J&J, NewLink Ebola vaccines to clinical trials. FierceVaccines story | Follow @EmilyMFierce

> Edison's orphan drug misses the mark in Phase II. Story

> Lilly claims another head-to-head victory over Lantus in PhIII diabetes showdown. Report

> J&J teams with Bavarian Nordic on an emergency Ebola vaccine program. More

Pharma News

@FiercePharma: Tops on FPMarketing Weds: Can Sanofi/Regeneron's new data one-up Amgen in megablockbuster PCSK9 field? Article | Follow @FiercePharma

@EricPFierce: Agents in EU seize €10M worth of counterfeit drugs, as well as cash and luxury cars, arrest a dozen. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Sanofi's dengue shot ups serotype 2 protection rate in final trial. FierceVaccines story | Follow @CarlyHFierce

> AstraZeneca pressed Obama for help resisting Pfizer's tax-cutting buyout bid. Article

> NICE slaps unusual rules on Alexion's pricey Soliris after atypical cost review. More

> Payers beware: Bristol-Myers prices PD-1 cancer med at $143,000 in Japan. Story

Vaccines News

> FDA rushes J&J, NewLink Genetics Ebola vaccines to clinical trials. Article

> Study: Old HIV pediatric vaccines might provide protection after all. Item

> Amid Bexsero negotiations, Novartis medical director slams U.K. vaccine assessment system. More

> Sanofi's dengue shot ups serotype 2 protection rate in final trial. Story

> Amgen submits melanoma-fighter T-Vec to EMA on the heels of its FDA filing. Report

Pharma Manufacturing News

> Theratechnologies returns HIV product Egrifta to U.S. Item

> Wockhardt expects to resolve most FDA concerns within the year. Report

> China sweeps up gang that made and sold 90M toxic capsules. More

> Actavis production not meeting demand for new version of Alzheimer's drug. Story

> Xellia lays out $100M expansion plan for new U.S. facility. Article

Suggested Articles

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.